
Director, Medical Biology @variantbio | MD, DPhil @bdi_oxford @Oxford_NDPH | Prev: @OpenTargets
Seattle, WA
Joined March 2010
- Tweets702
- Following494
- Followers196
- Likes3.2K
Pinned Tweet
Our @NEJM letter is out!
@targetvalidate genetics data used to identify associations of the ABO locus with CD209 (an entry receptor for SARS-CoV-2, biorxiv.org/content/10.1101/…), with similar reports from others.
With @DunhamReal @MayaGhoussaini
nejm.org/doi/full/10.1056/NE…
Mohd Anisul Karim retweeted
Announcing our newest paper on the genetics of kidney disease co-authored with research partners from South Africa and Uganda: medium.com/variantbio/new-pu…
Mohd Anisul Karim retweeted
Findings from our recent papers in @ScienceMagazine and @NatureComms include health risks and drug-target leads the largest databases miss: medium.com/variantbio/two-pa…
Mohd Anisul Karim retweeted
Out today on the cover of @ScienceMagazine: work led by @KeoluFox (UCSD) and Alexander Ioannidis (Stanford) with @VariantBio. Polynesians experienced founder effects 10x stronger than Finland’s, with big implications for drug discovery and clinical care: science.org/doi/10.1126/scie…
Mohd Anisul Karim retweeted
Variant Bio leverages AI-powered Inference platform in an expanded collaboration with @Boehringer: medium.com/variantbio/expand…
Mohd Anisul Karim retweeted
The best signal in a partnership is when both sides want to do more.
This week, BI and Variant Bio are expanding our collaboration into CVD, combining BI's expertise with our proprietary data and AI-powered platform.
Grateful to the teams on both sides who made this happen.
Thrilled to announce our latest drug development collaboration! We are now expanding our existing partnership with @Boehringer into cardiovascular disease for a total potential deal value exceeding $250 mm: prnewswire.com/news-releases…
Mohd Anisul Karim retweeted
"Real world data" is an almost meaningless phrase. Our new @bmj_latest paper pushes the more helpful phrase "routinely collected data" and explains the many limitations of such for research purposes. doi.org/10.1136/bmj-2025-087… #Statistics
Mohd Anisul Karim retweeted
Pakistan Genomic Resource (PGR), founded by Danish Saleheen, is the world's largest genetic database of human knockouts. It has been quietly building since 2017, from 10,000 individuals (Saleheen et al. Nature 2017) to nearly 200,000 today.
A new paper in Nature by Koch et al. reports a new analysis of 173,303 Pakistanis from PGR, offering genetic insights from natural inbreeding experiments in humans.
Koch et al. Nature 2026
nature.com/articles/s41586-0…
In biology, to understand what a gene does, you delete it, a standard experiment. Knock out the gene in a mouse and see what breaks: organ fails, behaviour changes, animal dies. Thirty years of biology built this way. It works, until it doesn't. Because, you know, mice are not humans.
To know the function of a gene in humans, you need a similar experiment. But that's unethical, you cannot deliberately delete a gene in a human. Except you don't have to, because nature has already been doing that experiment.
Occasionally, a person inherits a broken copy of a gene from both parents and is born with no working version at all--a human knockout. The problem is finding them. In most of the world's populations, where mating is largely random, these events are nearly invisible. For a gene-inactivating variant at 0.1% frequency, you'd expect one homozygous individual in every million people.
That math collapses in populations like Pakistan, where consanguineous marriage has been practised for centuries. In first-cousin marriages, the odds of observing a human knockout for the same 0.1% variant rise to roughly 1 in 16,000, a 63-fold enrichment. And the rarer the variant, the larger the advantage: ~630-fold for a 0.01% variant, ~6,300-fold for a 0.001% variant. The variants too rare to ever be seen in European biobanks become findable here.
Sequencing more than 170,000 individuals from highly consanguineous communities, the authors report a mind blowing statistic: at least one living human knockout was observed for 6,476 genes, which is nearly 1/3rd of the entire protein-coding genome!
What do we find when we finally have the human knockouts?
Studying the phenotypes in the human knockouts helps us confirm or refute our understanding of the gene's function based on animal studies. A few examples I highlight below.
PRDM9
PRDM9 might be one of the most popular genes among animal biologists. It encodes a protein that controls where chromosomes break and recombine during sperm and egg formation. Deleting the gene has caused infertility in every animal. PRDM9 was classified as the first hybrid sterility gene in vertebrates, so fundamental that crosses between mouse species with different PRDM9 alleles can't produce a fertile offspring. PGR now has 4 human PRDM9 knockouts : three women, one man. All fertile, with 2 to 7 children each. A 14-year biological fact, overturned by four families in Pakistan.
LRRK2
LRRK2 is a well-established Parkinson's disease risk gene. Activating mutations in LRRK2 are among the most common risk factors for Parkinson's. LRRK2 is a therapeutic target with many companies exploring ways to switch off this gene in the brain to treat Parkinson's. Large-scale sequencing studies have found individuals with partial loss of LRRK2, who did not show any concerning health issues, predicting adverse effects of LRRK2 inhibition in humans. Animal knockouts though warned of kidney damage. Now PGR has two LRRK2 knockouts, both with kidney disease, confirming animal studies.
RXFP1
RXFP1 encodes the receptor for a pregnancy hormone called relaxin, which has long been studied in rodents. Animal studies suggested it played a critical role in cardiovascular adaptation and connective tissue remodelling, fuelling relaxin-targeted drug development, which failed in late-stage trials. PGR found 16 RXFP1 knockouts, expanded to 26 via recall-by-genotype, all tested with cardiac imaging. None had consistent cardiovascular or reproductive deficits, retrospectively explaining the failure of relaxin-targeted drug programmes that might have spent millions of dollars. Mouse physiology failed to inform humans in the case of relaxin.
Gene constraint insights
Existing large-scale biobanks are predominantly European-based outbred populations, which shaped our understanding of gene constraints largely based on intolerance to partial loss of function. Now PGR, a South Asian-based cohort enriched for consanguineous communities, is beginning to offer insights into gene constraints based on intolerance to complete loss of function.
PGR showed that nearly 1/3rd of human genes tolerate complete loss of function. As much as the genes for which knockouts were found, the genes for which knockouts weren't found can offer biological insights.
The authors find genes depleted for knockouts in PGR are enriched for genes essential for cell survival, known Mendelian disease genes (both dominant and recessive) and genes broadly expressed across human tissues.
A fascinating insight is significant enrichment for knockouts in tissue-specific genes (OR=2.39). Human knockouts confirm what drug developers have always thought: tissue-specific genes are much safer therapeutic targets than broadly expressed genes.
The above insight should be read with caveats. The sample size of PGR is small, hence not saturated for human knockouts. It's likely the number of genes will increase as the sample size grows. There is a survivorship bias, like any other volunteer-based cohort. Absence of a gene knockout here doesn't mean biological impossibility. It means incompatibility with being a 'healthy' adult volunteer. If you build a cohort based on a hospital-based pediatric rare disease South Asian cohort, you'd expect to see knockouts that never appeared in PGR.
South Asian populations represent nearly a quarter of humanity, yet they have been largely absent from the genomic revolution. PGR shows what absence has been costing the field: overturned biological assumptions, failed trials, missed targets. The biology was always there. We just weren't looking in the right place.
Mohd Anisul Karim retweeted
A monumental moment in medical history: the first gene therapy for genetic hearing loss is now FDA approved. As a former Regeneron scientist, I feel very proud. I had the opportunity to hear about this programme while it was still in development. It’s one of the few programmes that, every time you came across it, you felt the medical breakthrough in your bones and privileged just to be there while it was happening.
At this moment, it’s important that we look 30 years back when researchers mapped a locus on chromosome 2 to congenital deafness in a Lebanese family (pubmed.ncbi.nlm.nih.gov/8789…). They named it DFNB6 (later DFNB9) with no clue about the responsible gene. Three years later, the causal gene came to light: OTOF, encoding a protein called otoferlin (nature.com/articles/ng0499_3…). Seven years after that, in 2006, pioneering work by Christine Petit revealed that otoferlin is a calcium sensor in the inner hair cell membrane, acting as a molecular trigger that converts sound into electric signals that the brain can read (pubmed.ncbi.nlm.nih.gov/1705…). Twenty years fast forward, we now have a successful treatment. Thirty years from discovery to medicine.
OTOF-related deafness is congenital, caused by complete deficiency of otoferlin. In these children, the cochlea is structurally intact, hair cells are there, the mechanics of sound transmission work. It’s just that final step, where hair cells hand off the signal to the auditory nerve through neurotransmitter release, that doesn’t happen. Sound arrives and dies at the synapse. It’s deafness due to a defect in the synapse caused by the absence of a single protein, which is what made this a beautiful, clean target for gene therapy.
The treatment itself is a feat of molecular engineering. OTOF is too large to fit in a single AAV capsid. The team solved this elegantly by delivering the gene in two halves separately, which then get spliced to produce the full functional protein. A single surgical injection into the cochlea, a molecular miracle unfolds. Results from the CHORD trial were striking: of 20 evaluable patients, including children as young as 10 months, 80% showed meaningful hearing improvement, and by 48 weeks, 42% had achieved normal hearing including the ability to hear whispers. Otarmeni is not only the first gene therapy for deafness, it’s also the first dual-AAV therapy to be approved by the FDA.
There are very few things in medicine that come close to giving back a sense like vision, hearing, or touch that a human never had from birth. It’s almost God’s work. A parent witnessing their child who was born deaf hearing their voice for the first time, it’s a joy that no words can describe. Multiply that by the fact that it came from a single injection, a repaired gene, and 30 years of science. We are truly in the golden era of medicine.
Regeneron press release:
investor.regeneron.com/news-…
Below video is from the NEJM publication of CHORD trial (Valayannopoulos et al. NEJM 2025)
nejm.org/doi/full/10.1056/NE…
I know a lot of people have strong opinions on the hype around this story. He isn’t claiming he cured his dogs cancer. To me, the real story is how far a person with no background in biology but so much love for his dog can go with open source tools!
A lot of people have been asking if this can be done for their dogs and for people. I'm speaking with everyone involved to see what is possible here.
If you would like to be involved, please complete the following Google form:
bit.ly/4bkaowg
47
Mohd Anisul Karim retweeted
I’d love to connect with academic scientists working in genomics across India 🇮🇳
Interested in learning about ongoing work and exploring opportunities for collaboration around disease-centric, hypothesis-driven clinical and genomic datasets.
If you’re working in this space, please reach out or point me to others I should know.
Mohd Anisul Karim retweeted
Sputtering? Zero chances. I’m empathetic to the personal stories, but don’t think these anecdotes reflect the reality on the ground. I’m feeling more positive now than in years.
Biotech is a cyclic business. We had a bubble of overbuilding, overhiring, and overfunding, followed by retrenchment for a couple years. We’re in a healthier place now. We still have 2x more VC funding in biotech than a decade ago. IPOs dried up but are coming back. XBi is up significantly. And we’re now entering an expansion part of the cycle.
Lab vacancy rates have more to do with the massive lab build out, creating a huge glut of supply, than a long term pullback in biotech relative to pre-pandemic bubble lab usage. Ridiculous rents in the face of demand drove overbuilding of labs, which take years to come online - thus the glut today.
I’m an optimist on the sector and on Kendall specifically. Interest rates, M&A, catalytic data, sector rotation into biopharma, and fading macro risks all create tailwinds. Boston remains the global epicenter of biopharma R&D. In the US, I’m concerned about further FDA chaos, but am hopeful we can manage thru that…
China is both threat and opportunity - bringing new drugs to patients globally is a good thing. And raising the competitive pressure to do things faster and cheaper in the US is healthy. Appropriate regulatory changes need to happen, and I think will over time.
But fundamentally the Boston biotech cluster, and the western biotech sector more broadly, are poised for a renewed positive run over the next few years.
The reports of our death, or sputtering, are greatly exaggerated…
Why are genes ranked differently in LoF burden tests vs GWAS for the same trait? @jkpritch lab & colleagues investigate sources of these differences and how these differences are a 'blessing', complementing different aspects of disease biology. nature.com/articles/s41586-0…
1
1
38
One point they made reminded me of our discussion @doctorveera of predictive value of CV vs RV on clinical impact of GLP1Rs
1
26
Mohd Anisul Karim retweeted
Novo, @VariantBio deal is a win for benefit sharing agreements with indigenous people. First time significant $ will flow back to an indigenous community that contributed. Listen to CEO Andrew Farnum discuss the idea on The Long Run (Nov. 2020) timmermanreport.com/2020/11/…
Mohd Anisul Karim retweeted
Our platform at Variant has unveiled more targets than we could ever advance on our own, and we have a moral responsibility to ensure our findings are given the best shot to become lifesaving drugs. We couldn’t ask for a better partner than Novo Nordisk to work with us on metabolic disease…
We are collaborating with Novo Nordisk to discover novel targets for the treatment of metabolic disease: medium.com/variantbio/varian…
Metabolic disease manifests and impacts different population groups differently.
Using the lens of human genetics from diverse pop groups, can we dissect novel causal biology of metabolic diseases?
Our collaboration with Novo Nordisk seeks to explore this q and more 👇🏼
We are collaborating with Novo Nordisk to discover novel targets for the treatment of metabolic disease: medium.com/variantbio/varian…
3
105
I think most people wouldn’t have heard of the infectious diseases (guinea worm, river blindness etc) affecting millions in Africa had it not been for this man. His foundation nearly eradicated guinea worm disease and saved millions of people from river blindess. RIP Pres Carter!
President Carter taught all of us what it means to live a life of grace, dignity, justice, and service. Michelle and I send our thoughts and prayers to the Carter family, and everyone who loved and learned from this remarkable man. barackobama.medium.com/our-s…
1
123
“Nothing about us without us”. Read about @VariantBio’s approach to co-creating biomedical knowledge with participating communities starting from Day 1 until results return and beyond. 🧬🧬
Our recent Commentary in @CellCellPress provides practical examples of how to share results with communities participating in genomic research: medium.com/variantbio/varian…
3
70
Mohd Anisul Karim retweeted
The Open Targets Platform autumn release 🍁 is full of new data and UI features. This is the last update before we make a giant leap forward in our common genetic evidence 🧬
Mohd Anisul Karim retweeted
Great to see this paper out by @D_Westergaard and colleagues - including myself - leveraging the just jaw-droppingly good combination of the Danish pedigree data (across the entire country!) and their highly detailed EHR. nature.com/articles/s41467-0…
















